Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05398536
Other study ID # ssaka6
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 8, 2018
Est. completion date December 20, 2018

Study information

Verified date May 2022
Source Halic University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Kinesiophobia is a common problem in patients with rheumatic disease and can cause physical inactivity, social isolation, disability, and poor quality of life. This study aimed to evaluate kinesiophobia and associated factors in patients with familial Mediterranean fever (FMF). All patients were evaluated in terms of sociodemographic characteristics and assessed using the Tampa Kinesiophobia Scale (TKS), International Physical Activity Questionnaire (IPAQ), Fatigue Severity Scale (FSS), and Hospital Anxiety and Depression Scale (HADS).


Description:

Familial Mediterranean fever (FMF) is a common autoinflammatory disease among certain ethnic groups living in the Mediterranean basin. The reported prevalence of FMF among children in Turkey is 9.3/10000. Kinesiophobia is a common problem in patients with rheumatic disease and can cause physical inactivity, social isolation, disability, and poor quality of life. This study aimed to evaluate kinesiophobia and associated factors in patients with familial Mediterranean fever (FMF). All patients were evaluated in terms of sociodemographic characteristics and assessed using the Tampa Kinesiophobia Scale (TKS), International Physical Activity Questionnaire (IPAQ), Fatigue Severity Scale (FSS), and Hospital Anxiety and Depression Scale (HADS).


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date December 20, 2018
Est. primary completion date March 27, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - being age over 18 - being volunteer Exclusion Criteria: - ortopedic, neurologic, cardiopulmonary diseases that prevent physical activity - psychological diagnosis and drug usage

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey Haliç University Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Halic University

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Giese A, Örnek A, Kilic L, Kurucay M, Sendur SN, Lainka E, Henning BF. Anxiety and depression in adult patients with familial Mediterranean fever: a study comparing patients living in Germany and Turkey. Int J Rheum Dis. 2017 Dec;20(12):2093-2100. doi: 10 — View Citation

Oskay D, Tuna Z, Düzgün I, Elbasan B, Yakut Y, Tufan A. Relationship between kinesiophobia and pain, quality of life, functional status, disease activity, mobility, and depression in patients with ankylosing spondylitis. Turk J Med Sci. 2017 Nov 13;47(5): — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Tampa Kinesiophobia Scale (TKS) The TKS consists of 17 items scored on a 4-point Likert scale and measures fear of movement/(re)injury. The questions include the parameters of injury/reinjury and fear-avoidance in work-related activities [15]. The total score is obtained by summing all items, and a higher score indicates greater fear of movement. A total score greater than 37 is regarded as indicating a high level of kinesiophobia at the enrollment
Primary Hospital Anxiety and Depression Scale (HADS) The scale consists of 14 items divided into the depression and anxiety subscales, each with 7 items. The items on the scale are scored from 0 to 3 using a 4-point Likert scale. The scores of the odd-numbered items are summed to obtain the anxiety subscale (HADS-A) score and the even-numbered items are summed to obtain the depression subscale (HADS-D) score. Possible scores for each subscale range from 0 to 21. at the enrollment
Primary International Physical Activity Questionnaire (IPAQ) In the IPAQ, respondents estimate how often and for how long they engaged in various activities in the last 7 days. To determine PA levels, the known metabolic equivalent (MET) for each activity is multiplied by its duration and frequency to obtain a score in MET minutes. MET values used in this study were 8.0 for vigorous physical activity (VPA) [8, 19], 4.0 for moderate physical activity (MPA), and 3.3 for light physical activity (LPA). The overall PA score is calculated by summing the results of all items [20]. PA levels were classified into 3 categories: inactive (<600 MET-min/week), low PA level (600-3000 MET-min/week), and adequate PA level (>3000 MET-min/week) at the enrollment
See also
  Status Clinical Trial Phase
Recruiting NCT05190991 - Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever Phase 2
Recruiting NCT03210610 - Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) Patients
Not yet recruiting NCT06336733 - Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy Phase 3
Not yet recruiting NCT05292768 - Are Mast Cells Involved in Autoinflammatory Diseases
Enrolling by invitation NCT04402255 - Pilates Based Exercises in Patients With Behçet and Familial Mediterranean Fever. N/A
Completed NCT02466217 - Phenomics in Autoimmune and Inflammatory Diseases
Recruiting NCT05980780 - The Effect of Video Game on Children With Familial Mediterranean Fever N/A
Not yet recruiting NCT06047938 - FMF and Atheroscelerosis
Recruiting NCT05092776 - Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine Phase 2
Enrolling by invitation NCT04403438 - Familial Mediterranean Fever and Behçet: Analysis Before and After Covid19 Pandemic